Cellectis S.A. (EPA: ALCLS)
France
· Delayed Price · Currency is EUR
1.514
-0.026 (-1.69%)
Jan 20, 2025, 5:35 PM CET
Cellectis Revenue
Cellectis had revenue of $18.05M USD in the quarter ending September 30, 2024, with 997.99% growth. This brings the company's revenue in the last twelve months to $36.04M, up 46.96% year-over-year. In the year 2023, Cellectis had annual revenue of $9.19M, down -64.26%.
Revenue (ttm)
$36.04M
Revenue Growth
+46.96%
P/S Ratio
3.84
Revenue / Employee
$163.09K
Employees
221
Market Cap
151.54M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 48.45B |
EssilorLuxottica Société anonyme | 25.83B |
Sartorius Stedim Biotech | 2.74B |
bioMérieux | 3.81B |
Ipsen | 3.44B |
Eurofins Scientific SE | 6.72B |
Virbac | 1.34B |
Ramsay Générale de Santé | 5.01B |
Cellectis News
- 5 days ago - Cellectis S.A announces potential resale of up to 44M shares - Seeking Alpha
- 5 weeks ago - Cellectis: Poised To Start Answering Questions In 2025 - Seeking Alpha
- 5 weeks ago - Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) - Benzinga
- 5 weeks ago - Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) - GlobeNewsWire
- 2 months ago - Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting - GlobeNewsWire
- 2 months ago - Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - GlobeNewsWire
- 2 months ago - What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings - GuruFocus